Evidence map›Paper›PMID 30158280›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2018

Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer.

Meira Epplein, Julia Butt, Yang Zhang, Laura H Hendrix, Christian C Abnet, Gwen Murphy, Wei Zheng, Xiao-Ou Shu, Shoichiro Tsugane, You-Lin Qiao and 10 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  2. World journal of gastrointestinal oncology · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Serum antibodies to selectedMalawi medical journal : the journal of Medical Association of Malawi · 2022
    Article
  7. Frontiers in microbiology · 2022
    Review
  8. Article
  9. What Is New inJournal of clinical medicine · 2021
    Review
  10. Screening for gastric cancer in China: Advances, challenges and visions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021
    Article
  11. Racial Differences inCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  12. Review
  13. Smoking,Cancer prevention research (Philadelphia, Pa.) · 2019
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 7 countries.

Meira Epplein *Duke University, Durham, North Carolina.ORCID 0000-0001-5646-6430
Julia ButtGerman Cancer Research Center, Heidelberg, Germany.ORCID 0000-0001-7738-8611
Yang ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Laura H HendrixDuke University, Durham, North Carolina.
Christian C AbnetNational Cancer Institute, Rockville, Maryland.
Gwen MurphyNational Cancer Institute, Rockville, Maryland.
Wei ZhengVanderbilt University, Nashville, Tennessee.
Xiao-Ou ShuVanderbilt University, Nashville, Tennessee.
Shoichiro TsuganeNational Cancer Center of Japan, Tokyo, Japan.
You-Lin QiaoChinese Academy of Medical Sciences, Beijing, China.
Philip R TaylorNational Cancer Institute, Rockville, Maryland.
Taichi ShimazuNational Cancer Center of Japan, Tokyo, Japan.
Keun-Young YooSeoul National University, Seoul, Republic of Korea.
Sue K ParkSeoul National University, Seoul, Republic of Korea.ORCID 0000-0001-5002-9707
Jeongseon KimNational Cancer Center of Korea, Gyeonggi-do, Republic of Korea.
Sun Ha JeeYonsei University, Seoul, Republic of Korea.
Tim WaterboerGerman Cancer Research Center, Heidelberg, Germany.
Michael PawlitaGerman Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-4720-8306
Wei-Cheng You *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Kai-Feng PanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. pan-kf@263.net weichengyou@yahoo.com meira.epplein@duke.edu.
German Cancer Research Center · DEMinistry of Education · ETNational Cancer Institute · MYDuke University · USNamseoul University · KRNational Cancer Centre Japan · JPVanderbilt University · USChinese Academy of Medical Sciences & Peking Union Medical College · CNNational Cancer Center · USYonsei University · KR

Funding

Nutrition Intervention Trials in Linxian ChinaZIACP000112 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$8.2M
Helicobacter pylori blood biomarker for gastric cancer risk in East AsiaR01CA174853 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI EPPLEIN, MEIRA · 2013 to 2016
$2.3M
Helicobacter pylori subtypes, inflammation, and gastric cancer riskK07CA151782 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI EPPLEIN, MEIRA · 2011 to 2015
$629k
NCI NIH HHS K07 CA151782NCI NIH HHS R01 CA174853
6 · The paper itself

Abstract

background

methodsThis cross-sectional study included 1,402 individuals from Linqu County screened by upper endoscopy.

resultsCompared with individuals seronegative to Omp and HP0305, individuals seropositive to both were seven times more likely to have precancerous lesions (OR, 7.43; 95% CI, 5.59-9.88). A classification model for precancerous lesions that includes age, smoking, and seropositivity to

conclusionsThe present study of prevalent precancerous gastric lesions provides support for two new serum biomarkers of gastric cancer risk, Omp and HP 0305. IMPACT: Our results support further research into the serological biomarkers Omp and HP0305 as possible improvements over the established virulence marker CagA for identifying individuals with precancerous lesions in East Asia.

Indexed as

BiomarkersCross-Sectional StudiesFemaleHumansMaleRisk FactorsStomach NeoplasmsBiomarkers

Identifiers

PMID30158280
PMCPMC6279536
OpenAlexW2889019410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.